Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

BIZARRE: Kod | Mind Blowing Facts

Kodiak Sciences More Than Doubles on Eye Disease Trial Results

Kodiak Sciences reported strong endpoint results for its late-stage eye injection candidate, sending its stock soaring.

Barchart · Oct 1

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.

MarketBeat · Sep 13

Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday

U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Thursday.

Benzinga · Sep 25, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

On the latest edition of CNBC's “Mad Money Lightning Round,” Jim Cramer called Kodiak Sciences Inc. (NASDAQ:KOD) is a “pure spec” stock.

Benzinga · Aug 27, 2025

Gurugram: Govt cancels KOD's lease & seals gates over Rs 208 crore dues, penalty

GURUGRAM: Urban development agency HSVP sealed the premises of the Kingdom of Dreams (KOD) on Friday after cancelling its land lease agreement for not clearing dues amounting to around Rs 208 crore.

The Times of India · Jul 16, 2022

Expert Ratings For Kodiak Sciences

Analysts have provided the following ratings for Kodiak Sciences (NASDAQ:KOD) within the last quarter:

Benzinga · Feb 24, 2022

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study

Benzinga · Feb 23, 2022

Read news from The Economist, FT, and more,
with one subscription

Why Kodiak Sciences Shares Are Plunging Today

Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.

Benzinga · Feb 23, 2022

Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences

Barclays has lowered the firm's price target on Kodiak Sciences Inc (NASDAQ: KOD

Benzinga · Feb 7, 2022

What 4 Analyst Ratings Have To Say About Kodiak Sciences

Within the last quarter, Kodiak Sciences (NASDAQ:KOD) has observed the following analyst ratings:

Benzinga · Feb 1, 2022

Coverage From

People

Jim Cramer

550 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.